Clinical Approach for the Treatment of Obesity-associated Diseases

Author(s): Esma R. Isenovic

Journal Name: Current Pharmaceutical Design

Volume 25 , Issue 18 , 2019

Become EABM
Become Reviewer

[1]
Gouni-Berthold I, Berthold HK. Current options for the pharmacotherapy of obesity. Curr Pharm Des 2019; 25(18): 2019-32.
[2]
Radak D, Tanaskovic S, Neskovic M. The obesity-associated risk in open and endovascular repair of abdominal aortic aneurysm. Curr Pharm Des 2019; 25(18): 2033-7.
[3]
Cӑtoi AF, Vodnar DC, Corina A, et al. Gut microbiota, obesity and bariatric surgery: Current knowledge and future perspectives. Curr Pharm Des 2019; 25(18): 2038-50.
[4]
Katsiki N, Anagnostis P, Kotsa K, Goulis DG, Mikhailidis DP. Current options for the pharmacotherapy of obesity. Curr Pharm Des 2019; 25(18): 2051-9.
[5]
Tan Y, Chen S, Zhong J, Ren J, Dong M. Mitochondrial injury and targeted intervention in septic Cardiomyopathy. Curr Pharm Des 2019; 25(18): 2060-70.
[6]
Joksić G, Tričković JF, Joksić I. Potential of Gentiana lutea in treatment of obesity-associated diseases. Curr Pharm Des 2019; 25(18): 2071-6.
[7]
Yu W, Zha W, Peng H, Wang Q, Zhang S, Ren J. Trehalose protects against insulin resistance-induced tissue injury and excessive autophagy in skeletal muscles and kidney. Curr Pharm Des 2019; 25(18): 2077-85.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 25
ISSUE: 18
Year: 2019
Page: [2017 - 2018]
Pages: 2
DOI: 10.2174/138161282518190822153931

Article Metrics

PDF: 24
HTML: 5